Checkpoint inhibitor therapy for skin cancer may be safe in patients with asymptomatic COVID-19

Ann Oncol. 2021 May;32(5):674-676. doi: 10.1016/j.annonc.2021.02.008. Epub 2021 Feb 16.

Authors

C Trojaniello¹, M G Vitale¹, P A Ascierto²

Affiliations

¹ Department Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy.
² Department Melanoma, Cancer Immunotherapy and Development Therapeutics, Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy. Electronic address: paolo.ascierto@gmail.com.

No abstract available

Publication types

Letter

MeSH terms

COVID-19*
Coronavirus Infections*
Humans
SARS-CoV-2
Skin Neoplasms* / drug therapy